Psychedelic nasal spray shows promise for alcohol addiction in small trial
NCT ID NCT05674929
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a single nasal spray dose of BPL-003, a psychedelic drug, combined with psychological support in 13 adults with moderate to severe alcohol use disorder. The main goals were to check safety and tolerability, and to explore effects on drinking behavior. The study is complete, but results on effectiveness are not yet reported.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BPL-003 (a psychedelic drug given as a nasal spray)
What this could lead to
If successful, this could point toward a new treatment option for alcohol use disorder that combines a single drug dose with psychological support.
What could go wrong
This is a very small, early-phase study with only 13 participants, so results may not apply broadly. The drug may cause side effects or fail to reduce alcohol use in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clerkenwell Health
London, W1G 8DR, United Kingdom
-
King's College London
London, United Kingdom